Leaderboard Ad

Enhance your knowledge with education in Corporate Symposia

The following programs are planned and conducted by the corporate community in conjunction with AADE14. They provide attendees with additional education and information opportunities. Program content and product information are the sole responsibility of the corporate supporters. The first 30 minutes of each symposium will consist of a dinner.

1.5 CE available per session.
All events held at the convention center.

Physicians and physician assistants are welcome to attend Corporate Symposia; however, Corporate Symposia are not eligible for CME credits. Physicians and physician assistants may not claim AMA PRA Category 1 Credits™ for attending AADE Annual Meeting Corporate Symposia.

Ticketing Process

  • Look for the designated CS/PT Ticket Desk in the registration area. At this counter, attendees can obtain tickets to the various events. Note: Attendees are limited to one (1) ticket per event time. Seats are limited, so get your tickets early.
  • If you change your mind about attending, return the ticket to the
    CS/PT Ticket Desk.
  • Doors will open 30 minutes before the scheduled start time for attendees with a ticket.
  • Starting 15 minutes after the scheduled start time, organizers reserve the right to allow walk-ins to fill vacant seats. At this time, tickets will be voided.
  • If a ticket was not available at the CS/PT Ticket Desk, check at the door 15 minutes prior to the event to see if space is available.

 

Friday

5:30 pm – 7:30 pm

CS01: The People’s Choice: Matching T2DM Therapy to Give Patients What They Want and What They Need

Supported by an unrestricted educational grant provided by Novo Nordisk
Room W414

Learning Objectives

  1. Individualize treatment of T2DM using newer classes of agents for T2DM according to current patient-centered guidelines
  2. Assess patient outcomes using newer agents either alone or in combination with insulin therapy across T2DM progression
  3. Identify strategies to address the educational needs of patients using newer agents either alone or in combination with insulin to manage T2DM

This engaging, highly interactive symposium will discuss current patient-centered management guidelines for T2DM, with a focus on how newer antihyperglycemic agents, either alone or in combination with insulin therapy, can be used throughout the progression of T2DM. Participants will obtain new insights on key aspects of patient education using these agents, including glycemic efficacy, risk of hypoglycemia, nonglycemic effects, safety and tolerability, overcoming patient barriers, and encouraging treatment adherence. Understanding the benefits and limitations of a variety of treatment regimens will help diabetes educators to individualize therapy and enhance patient self-management, thereby improving behavioral, biological and quality-of-life outcomes for patients.

Davida Krueger, MSN, APN-BC, BC-ADM, (Program Chair), Certified Nurse Practitioner, Division of Endocrinology, Diabetes, Bone and Mineral Disease
James Gavin, III, MD, PhD, Clinical Professor of Medicine, CEO and Chief Medical Officer, Emory University School of Medicine; Healing Our Village, Inc.
Thomas Repas, DO, FACP, FACOI, FACE, CDE, Clinical Associate Professor, Sanford School of Medicine, University of South Dakota

UPN: 0069-9999-14-210-L01-P
LNC: 5190

CS02: Choose your Diabetes Treatment Adventure: Clinical Decision Points Using GLP-1 Receptor Agonists

Supported by an unrestricted educational grant provided by Lilly
Valencia Ballroom A

Learning Objectives

  1. Evaluate the latest data regarding available and emerging GLP-1 agonists, including mechanism, glycemic and nonglycemic benefits, and safety and tolerability data
  2. Appraise current recommendations for the treatment of type 2 diabetes, focusing on individualizing treatment goals and strategies using GLP-1 receptor agonists with respect to pharmacologic differences between agents and patient specific factors
  3. Using an audience driven, case-based approach, develop comprehensive, individualized treatment strategies for patients with type 2 diabetes focusing on key education and counseling points for patients who are beginning GLP-1 agonist therapy, switching between one GLP-1 agonist to another or adding GLP-1 agonist therapy to an existing treatment regimen

In recent years, the landscape of GLP-1 RAs has become decidedly more complex, and this trend will continue in the foreseeable future as more agents are approved. As the number of therapy choices increase, patients now have the option to change from one agent to another; also, as weekly-dosing regimens are approved, patients may prefer to discontinue daily therapy in favor of a more convenient schedule. This case-based presentation will employ a highly interactive, virtual-practice environment format, allowing the audience to “choose their diabetes adventure,” engaging CDEs in real-world practical strategies and clinical pearls on use of GLP-1 RAs.

Joe Largay, PA-C, CDE, (Activity Chair), Clinical Instructor, Department of Medicine – Division of Endocrinology, University of North Carolina
Lucia Novak, MSN, ANP-BC, BC-ADM, CDTC, Adjunct Assistant Professor, Uniformed Services University of the Health Sciences
Geralyn Spollett, MSN, ANP, CDE, Associate Director, Yale Diabetes Center

UPN: 0069-9999-14-205-L01-P
LNC: 5190

CS03: Diabetes Technology Comes of Age: Practical Strategies for Optimizing Integrated Insulin Pump Therapy and Continuous Glucose Monitoring

Supported by an unrestricted educational grant provided by Medtronic-Bayer Alliance
Valencia Ballroom BC

Learning Objectives

  1. Discuss how innovations in glucose monitoring and insulin delivery have affected diabetes complication risk
  2. Define the components of sensor-augmented pump therapy
  3. Recognize the importance of blood glucose meter accuracy in confirming patterns of glycemic control
  4. Summarize how patients and families can use downloadable data to manage diabetes more confidently

Recent advances in integrated diabetes management systems — such as threshold suspend automation that stops insulin delivery when continuous glucose readings fall below a predetermined level — have provided additional rationale for using integrated insulin pump and continuous glucose monitoring systems to keep glucose stable. This symposium will detail strategies for helping motivated patients and families use these systems to reduce hypoglycemia risk and manage diabetes more confidently. Interactive cases will engage attendees in thinking through how integrated (sensor-augmented) insulin pump therapy, supported by careful and accurate blood glucose monitoring, can be best applied in today’s healthcare landscape.

Irl B. Hirsch, MD, (Chairperson), Professor of Medicine, University of Washington School of Medicine
Elizabeth A. Nardacci, MS, FNP-BC, CDE, Nurse Practitioner, Albany Medical Center
Jennifer Block, FNP, NP-C, RN, CDE, CDTC, Nurse Practitioner and Research Nurse, Stanford University and Lucile Packard Children’s Hospital

UPN: 0069-9999-14-211-L01-P
LNC: 5190

CS04: Perspectives on SGLT2 Inhibition: Are We on a Course for Insulin-independent Pathways in T2DM Management?

Supported by an unrestricted educational grant provided by AstraZeneca
Valencia Ballroom D

Learning Objectives

  1. Explain the role of the kidney and the SGLT2 pathway in glucose reabsorption and the therapeutic basis of SGLT2 inhibitors for the treatment of T2DM
  2. Compare clinical trial data among the various SGLT2 inhibitors to discuss the risks and benefits of this class of agents
  3. Implement strategies that improve patient–provider communication to relay treatment expectations to patients with T2DM

Management of diabetes remains suboptimal, and a novel class of insulin-independent agents — the SGLT2 inhibitors that target the kidney — has recently been approved. A clear understanding of the mechanism of action of this class of therapy, the clinical trial data concerning their safety and efficacy, and more importantly, communication strategies that address patient questions and concerns regarding this new class of therapy, are all critical for the successful integration of this novel class of therapy in clinical practice. The above-mentioned factors, in addition to patient video vignettes, will be discussed in this case-based expert roundtable discussion activity.

Dwight Deter PA-C, CDE, DFAAPA, Clinical Faculty Associate, Southwest Endocrine Consultants; Clinical Assistant Professor, Texas Tech University Health Science Center
Debbie Hinnen, APRN, BC-ADM, CDE, FAAN, FAADE, Advanced Practice Nurse, Memorial Hospital, University of Colorado Health System
Anne Peter, MD, FACP, CDE, Director, Clinical Diabetes Programs; Professor, Keck School of Medicine, University of Southern California

UPN: 0069-9999-14-212-L01-P
LNC: 5190

While every effort is made to ensure the accuracy of data listed here, the publisher cannot be held responsible for errors or omissions.